Directorio

We are using this registry to learn more about acute aortic dissection from hospitals across the country.

We are doing this study to learn more about prostate cancer and whether certain treatments are related with different outcomes and patient experiences.

You will be in this study for about 122 weeks. The study has three parts called Screening, Treatment, and Follow up. During screening, which can last up to six weeks, doctors will do tests to see if you can join. If you qualify, you will be placed by chance into one of two groups. One group will get a study drug called anifrolumab, and the other will get a placebo, which looks like the medicine but has no active drug. You will also keep taking your regular medicines for polymyositis or dermatomyositis. You must stay on the same dose of your regular medicines for at least the first eight weeks of the study.

Copilot said: Participation in this study requires very little time. The research muscle biopsy will be done at the same time as the biopsy that is already planned as part of regular medical care. After that, no additional study visits or time commitments are needed.

We are doing this study to find out if an experimental drug called KTX-1001 (the study drug) is a safe and effective treatment for multiple myeloma. We want to identify the most appropriate dose and dosing schedule of the study drug for patients with multiple myeloma.

We are doing this study to compare a ketogenic diet (a diet with high fat, moderate protein, very low carbohydrate) versus a normal diet. We want to find out if it has any effect on survival time for people with glioblastoma multiforme (GBM). We also want to know how biomarkers change when people follow a ketogenic diet. A biomarker is a biological molecule found in blood, other body fluids, or tissues. Biomarkers may be a sign of a condition or disease and can be used to predict someone's response to a specific treatment.

We are doing this study to learn more about what causes glioblastoma (GBM), a type of brain cancer, and the factors that affect GBM patients' quality of life. This research will help us to understand why some people get GBM, including how their genes and health history may contribute to tumor development and progression.